Lancet Oncol. 2020 Jan 30
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.
Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, Gusenleitner D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Flaherty K, Larkin J, Robert C, Kefford R, Kirkwood JM, Hauschild A, Schadendorf D, Long GV
Adjuvant dabrafenib plus trametinib reduced the risk of relapse versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma in the p ...
Read More
Source: PubMed
Lancet Oncol. 2020 Jan 30
Adjuvant therapy for melanoma: how to choose?
Karakousis G
Read More
Source: PubMed
Drug Saf 2020 Jan 31
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.
Burmester GR, Curtis JR, Yun H, FitzGerald O, Winthrop KL, Azevedo VF, Rigby WFC, Kanik KS, Wang C, Biswas P, Jones T, Palmetto N, Hendrikx T, Menon S, Rojo R
Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). ...
Read More
Source: PubMed
Clin Transl Oncol 2020 Jan 31
SEOM clinical guideline for secondary prevention (2019).
Santaballa A, Pinto Á, Balanyà RP, Ramírez Merino N, Martín IR, Grau SS, Fombella JPB, Cano JM, González CH, Bayo J
Cancer is one of the major public health problems in our society. It is estimated that more than 18 million new cases are diagnosed worldwide every ye ...
Read More
Source: PubMed
Ann. Hematol. 2020 Feb 01
M2-like polarization of THP-1 monocyte-derived macrophages under chronic iron overload.
Kao JK, Wang SC, Ho LW, Huang SW, Lee CH, Lee MS, Yang RC, Shieh JJ
Macrophages are characterized by phenotypical and functional heterogeneity. In different microenvironments, macrophages can polarize into two types: c ...
Read More
Source: PubMed
Lancet Oncol. 2020 Jan 30
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.
Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, Gusenleitner D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Flaherty K, Larkin J, Robert C, Kefford R, Kirkwood JM, Hauschild A, Schadendorf D, Long GV
Adjuvant dabrafenib plus trametinib reduced the risk of relapse versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma in the p ...
Read More
Source: PubMed
Lancet Oncol. 2020 Jan 30
Adjuvant therapy for melanoma: how to choose?
Karakousis G
Read More
Source: PubMed
Drug Saf 2020 Jan 31
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.
Burmester GR, Curtis JR, Yun H, FitzGerald O, Winthrop KL, Azevedo VF, Rigby WFC, Kanik KS, Wang C, Biswas P, Jones T, Palmetto N, Hendrikx T, Menon S, Rojo R
Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). ...
Read More
Source: PubMed
Clin Transl Oncol 2020 Jan 31
SEOM clinical guideline for secondary prevention (2019).
Santaballa A, Pinto Á, Balanyà RP, Ramírez Merino N, Martín IR, Grau SS, Fombella JPB, Cano JM, González CH, Bayo J
Cancer is one of the major public health problems in our society. It is estimated that more than 18 million new cases are diagnosed worldwide every ye ...
Read More
Source: PubMed
Ann. Hematol. 2020 Feb 01
M2-like polarization of THP-1 monocyte-derived macrophages under chronic iron overload.
Kao JK, Wang SC, Ho LW, Huang SW, Lee CH, Lee MS, Yang RC, Shieh JJ
Macrophages are characterized by phenotypical and functional heterogeneity. In different microenvironments, macrophages can polarize into two types: c ...
Read More
Source: PubMed
